europabio-logoeuropabio-logoeuropabio-logoeuropabio-logo
  • About us
    • Who we are
      • Governance
      • Staff
      • Vacancies
    • What we do
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Cell & Gene Therapies
      • Medicines For Rare Diseases And Children
      • Regulatory Efficiency
      • Biosimilars & Public Procurement
      • Data & Digital
      • Patient Bio-Forum
    • Industrial Biotechnology Council
      • Food, Feed & Nutrition
      • Circular Bioeconomy
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
  • Activities
    • 25 Years of Innovation
    • EFIB 2022
    • European Biotech Week
  • Events
  • Newsroom
    • News & Publications
    • Library
Become a member
✕

EuropaBio response to the public consultation on the Roadmap for an EU Pharmaceutical Strategy

30/07/2020
POSITION PAPER
EuropaBio response to the public consultation on the Roadmap for an EU Pharmaceutical Strategy

EuropaBio response to the public consultation on the Roadmap for an EU Pharmaceutical Strategy Read through our views on the Roadmap for an EU Pharmaceutical Strategy

EuropaBio sees the Pharmaceutical Strategy as a crucial chance to strengthen the EU life sciences & biotechnology ecosystem; protecting citizens’ health and enhancing EU’s competitiveness vs US and China. COVID-19 has revealed the critical role of innovation in dealing with health emergencies. Of utmost importance is nurturing the bio-science sector and stimulating innovation to meet patient needs.

The research-based biotechnology industry is a core EU industrial sector. EuropaBio calls on the Commission to align its Pharma Strategy with the Industrial Strategy. Within the existing regulatory framework, all objectives of the Roadmap can be achieved. Increased collaboration of EU, Member States, public and private stakeholders will create solutions for value-based innovations.

Access & availability

Improved access to new treatments (ATMPs, OMPs) should be prioritised. A series of challenges relating to HTA and reimbursement must be overcome.

R&D of novel biotherapeutics requires streamlined regulatory processes: rapid centralised scientific advice procedures, continuous dialogue and re-evaluation for additional requirements, e.g. GMO. Flexible regulatory pathways used for COVID-19 medicines should be applicable to better address unmet medical needs: faster approval, rolling reviews, labelling flexibility, increased interactions with regulators.

The OMP legislation increased investors’ interest in biotechnology but more supportive measures are vitally important to drive future medicine development for rare diseases. Its framework should be preserved as only 5% of existing rare diseases have a treatment available. The definition of unmet need should better incorporate the needs of patients. Affordability & health systems sustainability

Affordability measures should be balanced against the need for both sustainable health systems and a viable, competitive biotechnology ecosystem.

Cost-effectiveness or therapeutic value should be considered through systematic patient feedback to fill evidence generation gaps (ATMPs). Early interaction between health authorities, HTA bodies and payers along with evidence generation in consultation with these stakeholders can lead to better access.

Financial schemes or performance-based agreements should be considered. Procurement through the Most Economically Advantageous Tender (MEAT) can be useful in exceptional cases of cross-border threats. It remains undesirable if used only for cost containment.

Innovation for unmet needs via digital & emerging technologies

IP & incentives are critical to encourage long-term investments in high-risk, complex research & diversified product development (ATMPs, OMPs). Access to capital remains a challenge when compared to the US and China. Caveating incentives or building in conditionalities will not increase patient access and will jeopardise European research competitiveness.

The EU needs a strong collaborative network involving EMA and national agencies with sufficient resources and the right expertise to anticipate increasing complexities linked with breakthrough innovation. Consideration should be given for continued use of non-legislative approaches to emerging technology which have proven effective in responding to COVID-19. Timely access to standardised data sets and streamlined GDPR implementation will enhance data use for cross-border scientific collaboration. High-quality RWD & AI must be harnessed as part of the planned EU Health Data Space. RWE should be supported by EU-wide measures. EU competitiveness & less dependence on non-EU manufacturing

Flexibility and funding must be improved for innovative biotechnology SMEs.

Supply chains of innovative treatments are global by necessity.

A strategic approach to support innovative manufacturing in the EU will ensure reliable supply and create high-skilled jobs for the future

EuropaBio Statement on the EU Pharmaceutical Strategy


Download
Share
Alexandra Simionca
Alexandra Simionca

Related posts

06/02/2023

Delivering Europe’s ambitions in rare disease


Read more
01/02/2023

Joint Statement: The Data Act is a leap into the unknown


Read more
31/01/2023

EuropaBio’s 2022 Patient BioForum sets out recommendations to address the challenges of patients with unmet medical needs and calls for multi-stakeholder approach


Read more
17/01/2023

EuropaBio launches SME BioForum in Rare Diseases


Read more

Important links

  • Delivering Europe’s ambitions in rare disease
  • Joint Statement: The Data Act is a leap into the unknown

Categories in our Newsroom

Subscribe for our newsletter

Subscribe to the EuropaBio newsletter to receive the latest news and developments in the Biotech sector!


Subscribe
EuropaBio-Logo-White

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 2600 biotech companies, 2300 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2023 Europabio. All Rights Reserved. Designed by EYAS
Become a member
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkLegal & Cookies